It was reported that pharmacological Janus kinase inhibition is effective against rapidly progressive ILD in dermatomyositis patients with anti-MDA5 Abs [28], suggesting that these drugs may also be useful for controlling ADs in RA patients. This evidence concerns the gene IFIH1 and interstitial lung disease.